Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placeboSPN-820 was well-tolerated ...

Supernus (SUPN) announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically ...

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...

CONTINUED... Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the m ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

A real-world study in Spain finds faster improvements with induction therapy but highlights long-term drug survival ...

This move reflects the company's belief in the potential of Bitcoin (BTC) and other currencies to provide a return on investment for shareholders and to provide some hedge against the Canadian dollar.

Discover why combining simvastatin and rifaximin does not offer a clinically meaningful advantage in preventing severe ...

Leading hair experts reveal when hair loss is normal and when it's time to worry, plus the proven solutions that actually ...

Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...

Organoids were cultured from healthy donor iPSC sources and differentiated using the human iPSC-derived Cerebral Organoid ...